Yellow Fever Pipeline Review 2021

Report Code: PMI461321 | Publish Date: February 2021 | No. of Pages: 132

Yellow Fever Pipeline Review 2021 Overview

Yellow Fever- Pipeline Review

Yellow fever is a viral disease spread by mosquitoes. The mosquito which causes yellow fever is mainly active and bite during daylight hours. Yellow fever is not a contagious disease, it doesn't spread from one infected person to another.

The virus in yellow fever is closely related to West Nile Virus. Yellow fever, mosquito’s flavivirus disease occurs in the tropical areas of sub-Saharan Africa, South America, parts of Central America and parts of the Caribbean. According to data published by Centres for Disease Control and Prevention (CDC), yellow fever virus is projected to cause 200,000 cases of disease and 30,000 deaths per year, with 90% occurring in Africa.

The U.S. Food and Drug Administration (FDA) has licensed Sanofi Pasteur’s new U.S. YF-VAX (Yellow Fever Vaccine) production facility and doses continue to progress through manufacturing. They expect to have more details on the return of YF-VAX in Q2, 2020. The Expanded Access Investigational New Drug Application Program (EAP) is projected to continue through 2020. Sanofi Pasteur has worked with the FDA in the U.S. to provide access to another yellow fever vaccine through this EAP. STAMARIL (Yellow Fever Vaccine [Live]) vaccine manufactured by Sanofi Pasteur in France, is registered and distributed in more than 70 countries. Individuals above 9 months of age suffering from an increased risk for yellow fever are given YF-VAX vaccine to prevent them from getting the disease.

Approximately 60% of pipeline drugs for yellow fever are in phase 2 clinical stage. Several government institutes and research organizations are conducting clinical trials combined with pharmaceutical companies to treat and prevent yellow fever.


Report Description

The report on Yellow Fever- Pipeline Review, 2020 provides comprehensive information regarding drugs in the pipeline by indication or molecule for yellow fever. The report provides a complete analysis of the stage of development, mechanism of action (MoA), drug target route of administration (RoA) and molecule type. The report helps in tracking and identifying emerging players in the market and their portfolios enhance decision-making capabilities and assists companies in developing growth strategies by providing a complete overview of R&D activities.

Report Scope

  • Assessment of pipeline products based on various stages of devolvement.
  • Provides an overview of the global therapeutic landscape of Yellow Fever (Infectious Disease).
  • Provides comprehensive details of pipeline products based upon companies and universities/research institutes overviews
  • The report provides descriptive features regarding drug profiles for the pipeline products which comprise, product description, R&D brief, descriptive licensing and collaboration details, MoA & other developmental activities.
  • Latest news, articles, press-release, and related conferences

Yellow Fever Pipeline Review 2021 Key Issues Addressed

  • Provides detailed analysis regarding significant competitor and insights to formulate effective R&D development strategies
  • Create effective counter-strategies to gain competitive advantage and identify emerging players with a potentially strong product portfolio
  • Build strategic initiatives by understanding the focus areas of leading companies
  • Identify strategies to diversify R&D focus to drive the growth in business and plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Analysis of the reason behind the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Yellow Fever Pipeline Review 2021 Table of Contents


  1. Introduction
  • Objectives of the Study
  • Definition
  • Report Overview
  • Yellow Fever Overview
  1. Executive Summary
  2. Yellow Fever: Pipeline Assessment
  • Company Overview
  • Product Description
  • Status
  • Phase
  • Study Design
  • Route of Administration
  • Indication       
  • Condition        
  • NCT Number              
  • Sponsor          
  • Collaborator   
  • Brief Title         
  • Study Start Date         
  • Study completion (Estimated/Actual)
  • Study Completion Date
  • Enrollment     
  • Research Location (Listed Location Countries)
  1. Yellow Fever: Analysis on Dormant & Discontinued Pipeline Candidates
  • Overview
  • Product Description
  • Reason for Discontinuation
  1. Yellow Fever: Additional Key Insights
  • Epidemiology Overview: Yellow Fever
  1. Yellow Fever: Press Releases, Latest News and Conference Details


  • Table of Content is tentative and subject to change as the research progresses
  • The drug candidates are included as examples in the pipeline when this ToC was designed and their status might have changed since then.